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Introduction: Abortifacient drugs, such as RU-486 or mifepristone, used in combination with a 
prostaglandin analogue (misoprostol) for the purpose of achieving medical abortion, have given rise 
to major legal, ethical and moral quandaries, which legislators all over Europe have striven to 
overcome by reconciling the reproductive rights of women with those of dissenting medical 
personnel.  
Materials and Methods: We have conducted a comparison between international legislative 
approaches from the 1970s to 2020 upon the subject of voluntary abortion, with an eye on their 
applicability as well as other ethical concerns, supported by the analysis of the scientific debate on 
medical vs surgical abortion. 
Results: The unresolved rift between the reproductive will of women and medical professionals’ 
claim to conscientious refusal to treat, i.e., refusal to perform abortions or to prescribe abortifacient 
medicine, in such overwhelming numbers in Italy and elsewhere, has given rise to the impossibility 
of many women to terminate their pregnancies as they choose to. As a matter of fact, in 2018, only 
64.9% of Italian public hospitals were able to guarantee access to abortion services. Hence, 35% of 
Italian facilities fail to meet the standards set by Law 194/78.  
Conclusion: The authors have aimed to shed light on how medical abortion is to be preferred over a 
surgical one, and how major European countries have dealt with such an extremely thorny issue that 
has polarised the public opinion and scientific community members alike. 
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Introduction 
RU-486 (mifepristone) is an active 
antiprogesterone and antiglucocorticosteroid 
agent, generally used in combination with a 
prostaglandin analogue (misoprostol) in order to 
bring about a medical abortion during 
pregnancy. Except for Poland, Ireland, and 
Malta, where abortion is banned, access to the 
medication is regulated throughout the 
European Union, albeit through varying, rather 
than uniform protocols, as reflected in Table 1 (1, 
2). Much like in the EU, in the United States and 
several Eastern European countries, as well as in 
India, China, and all countries where abortion is 
legal, mifepristone combined with misoprostol is 
the most widespread means to induce an 
abortion. The World Health Organization itself 
has deemed the drugs safe and effective (3, 4). 
Table 1.  Comparison between voluntary termination of pregnancy vs medical abortion in diferent 
european countries 
COUNTRY Voluntary Termination of 
Pregnancy 
Medical Abortion 
Austria Legal within the first 3 months 
of pregnancy (20). 
Legal and accessible. The regulation for 
mifepristone allows the drug to be 
administered only in medical facilities; 
medical abortion can therefore only be 
performed in hospitals (21). 
Belgium Legal within the twelfth week 
of pregnancy. 
Available in Belgium and given until up to 49 
days of amenorrhea (22). 
Bulgaria Legal within the twelfth week 
of pregnancy (23). 
Abortifacient drugs are not registered, thus 
illegal. 
Croatia Legal within the tenth week of 
pregnancy (24). 
Medical abortion has been available since 
2015. Only recently has the Croatian Agency 
for Medicinal Products and Medical Devices 
(HALMED) approved the drug combination 
used in medical abortion. Yet, their 
administration is only allowed in hospitals 
accredited to perform abortions, with 
professional supervision.  
Cyprus Legal within the tenth week of 
pregnancy since 2018 (25). 
Misoprostol is legally usable for termination 
of pregnancy. 
Czech Republic Legal within the first 3 months 
of pregnancy (26). 
Legal upon demand since 2013. 
Denmark Legal within the twelfth week 
of pregnancy since 1973 (27). 
Medical abortion is used until end of 8th 
week. Surgical abortion may be chosen until 
end of 12th week. Until 8th week, most 
abortions are medical. Overall, approx. 40% of 
all the abortions are medical and approx. 60% 
of all the abortions are surgical (28). 
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Estonia Legal within the eleventh 
week of pregnancy (29). 
Mifepristone in combination with misoprostol 
(Arthrotec) for the purpose of medical 
abortion was registered in 2003. Medical 
abortion can be used up to the 63rd day of 
pregnancy (30). 
Finland Legal within the twelfth week 
of pregnancy. Up to 20 weeks 
if there is a risk to physical 
health of woman or if the 
woman is younger than 17. Up 
to 24 weeks in case of major 
fetal malformation; no limit if 
there is the woman’s life is in 
danger (31). 
Legal and free of charge, on outpatient basis. 
France The ten-week limit was 
extended to the twelfth week 
in 2001 (32). 
France was the first country to legalize the 
use of RU-486 as an abortifacient in 1988, 
allowing its use up to seven weeks of 
pregnancy under medical supervision. 
According to a United Nations Population 
Division estimate, 19% of all French abortions 
used RU-486 as of 2002. Medical abortion 
represents almost 50% of all performed 
abortions. 
In response to the Covid-19 pandemic, 
France has extended access to medical 
abortions to nine weeks of pregnancy (33). 
Germany Legal within the first 3 months 
of pregnancy; mandatory 
counseling is required; 
abortion is also legal later in 
pregnancy in cases of medical 
necessity (34). 
Legal within 9 weeks (63 days) since last 
menstruation, requires medical prescription 
(35). 
Greece Legal within the first 3 months 
of pregnancy (36). 
Mifepristone and misoprostol are registered, 
available and affordable. However, medical 
prescription and hospitalization are required 
(37). 
Hungary Legal during the first twelve 
weeks of pregnancy (38). 
Banned 
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Ireland Legal since 2018 (following a 
constitutional amendment 
approved by a referendum in 
May 2018) within the twelfth 
gestational week and later in 
cases where the pregnant 
woman's life or health is at 
risk, or in the cases of a fatal 
fetal abnormality. 
Abortifacient drugs are illegal (39). 
Latvia Legal during the first twelve 
weeks of pregnancy (40). 
Legal and available since September 2008. 
Prescription and gynecological assistance 
are required. Medical abortion can also be 
carried out in certified in-patient facilities. 
Lithuania Legal during the first twelve 
weeks of pregnancy (41). 
Banned. 
Luxembourg Legal during the first twelve 
weeks of pregnancy, following 
two consultations with a 
medical doctor and a 
psychologist, and a waiting 
period of at least three days 
(42). 
Legal within 7 weeks (49 days) of pregnancy. 
Malta Banned under all 
circumstances. Malta is the 
only country in the European 
Union to ban abortion 
altogether (43). 
Banned. 
The Netherlands Legal during the first 24 weeks 
of pregnancy (i.e., when it is 
believed that the fetus has 
develop vital functions 
enabling it to live outside of 
the womb) (44). 
Legal (45). 
Poland Only legal in cases where the 
mother's life or health is at risk, 
in cases of major fetal 
malformations or pregnancy 
as a result of rape. 
Banned (46). 
Portugal Legal during the first ten 
weeks of pregnancy. 
Legal since 2007 (47). 
Romania Legal during the first fourteen 
weeks of pregnancy. 
Legal with prescription (48). 
Slovakia Legal during the first twelve 
weeks of pregnancy. 
Not available (49). 
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Slovenia Legal during the first ten 
weeks of pregnancy. 
Mifepristone available (50). 
Spain Legal within the 14th week of 
pregnancy, and at later stages 
in cases of serious risk to the 
health of the mother or fetal 
abnormalities. 
Legal within the first trimester of pregnancy. 
Not easily accessible and costly. Surgical 
abortions account for most termination of 
pregnancy procedures (51). 
Sweden Legal within the twelfth week 
of pregnancy (52). 
Medical abortion up to 63 days of pregnancy 
was approved in Sweden in 1992. Medical 
abortions accounted for 93% of all abortions 
in 2018 (53). 
United Kingdom Legal within 24 weeks of 
pregnancy (54). 
Mifepristone, approved for use in Britain in 
1991, and Misoprostol are legally accessible 
up to the ninth week (55). 
 
 
In Italy, the legislation enacted to regulate 
access to voluntary termination of pregnancy 
(Law 194/1978, titled “Norme per la tutela 
sociale della maternità e sull’interruzione 
volontaria della gravidanza”, or “Norms on the 
Social Protection of Motherhood and the 
Voluntary Termination of Pregnancy”), has 
effectively repealed Articles 545 to 555, which 
used to criminalise the termination of pregnancy 
in any way or form (5). 
As a continuation of this legislative 
development, following the completion of the 
experimentation process, RU-486 has been 
marketed in Italy since 10 December 2009. 
Nonetheless, it is worth noting that, unlike other 
European countries, where it was already legal 
to medically terminate a pregnancy up to 63 
days of amenorrhea, Italy has lowered that time 
limit to 49 gestational days. 
The impact that the “procreative revolution” has 
had on the awareness of the population, 
however, has pushed the Italian Supreme Court 
to issue rulings that have helped to overcome 
several legal and practical hurdles over the 
years (6, 7). 
 
Materials and Methods 
Materials and study design 
A large and qualitative review of the literature 
between the seventies and 2020 has been 
conducted to analyse the scientific background 
on medical and surgical abortion. The aim was to 
clarify the differences among the current laws 
and guidelines governing voluntary termination 
of pregnancy in different European countries, 
with an eye on the Italian situation, where the 
applicability of these laws is faced with ethical 
concerns. The study was conducted between 
2019 and 2020 at the Sapienza University of 
Rome, Department of Anatomical, Histological, 
Forensic and Orthopedic Sciences, in 
collaboration with the Department of Medical 
and Surgical Sciences, University of Foggia. 
Methods 
The authors have examined the main medical 
databases, e.g. Pubmed, Google Scholar, 
Scopus and Cochrane Library, as well as legal 
databases (Lexis, Justia, Kleagle) by applying 
effective combinations of terms, i.e. surgical 
abortion; conscientious refusal to treat; 
mifepristone; medical abortion; voluntary 
SEEMEDJ 2021, VOL 5, NO. 1 Medical vs Surgical Abortion 
188 Southeastern European Medical Journal, 2021; 5(1) 
 
termination of pregnancy; abortion guidelines; 
health standards; emergency contraception; 
conscientious objection; contraception; RU-486; 





The development and availability of new 
procedures and treatments undoubtedly entail 
novel ethical quandaries, at least theoretically. 
The issue of procreative freedom has unfolded 
along two distinct and irreconcilable lines of 
reasoning: if, on the one hand, medically assisted 
procreation has made it possible for women of 
relatively advanced age to achieve motherhood 
(8, 9), voluntary termination of pregnancy is in 
keeping with the woman’s will not to become a 
mother (10). Nowadays, access to abortion 
services, as codified in Italian statutes, presents 
considerable difficulties, even more so in cases 
of unplanned pregnancies, when contraceptive 
methods fail or when sexual abuse results in 
pregnancy. In fact, access to emergency 
contraception, which has positively contributed 
to lowering abortion rates, may not be easily 
available in a timely fashion (11-13). 
Contraceptive use rising as abortion falls: 
differences between Italy and European countries 
In 2018, more than 64.9% of Italian public 
hospitals guaranteed access to abortion 
services. Hence, 35% of Italian facilities fail to 
meet the standards set by Law 194/78 (11). 
One of the most relevant factors that led to such 
a situation is certainly conscientious refusal to 
treat by medical personnel, which is codified as 
a right in Law 194/78, under Article 9. According 
to said provisions, objectors may opt out of 
“performing procedures and activities 
specifically and necessarily aimed at achieving a 
termination of pregnancy” (14). Conscientious 
refusal to treat does not however exempt 
professionals from providing care before and 
after an abortion procedure or intervening in 
cases of emergency or imminent danger to the 
patient’s life.  After all, the Italian healthcare 
system is bound to uphold the free exercise of 
women’s right to sexual and reproductive 
freedom by guaranteeing access to abortion 
procedures through the services and 
professionals set in the provisions of Law 
194/78, by minimising the detrimental effects of 
conscientious refusal to treat under such a right, 
and possibly even ordering transfers of 
objecting physicians if no one else agrees to 
perform the procedure.  
The practical execution of such measures is 
undeniably complicated in a country such as 
Italy, where conscientious objectors account for 
roughly 70% of health care professionals (15), 
which is an extremely high share compared to 
the European average – 10% in the United 
Kingdom, 7% in France, and none in Sweden (16-
21). In most European countries, the law allows 
surgical abortion upon a woman’s request in the 
first weeks of pregnancy or in an advanced 
gestational period under certain circumstances 
(16-51) (Table 1).  
France was the first European country to legalise 
abortion by virtue of Law 75-17 of 17 January 
1975 (Law on the Termination of Pregnancy). 
According to the French law, every pregnant 
woman has the right to an abortion until the 
twelfth week of pregnancy. After this time limit, 
the French law consents to abortion only if the 
continuation of pregnancy proves to pose a real 
and serious danger to the woman’s health or life 
(16). In France, RU-486 has been legal since 
1988. The pill is administered within the first 
seven weeks of pregnancy and under medical 
supervision. In this country, medical abortions 
represent approximately 50% of all abortions 
performed. In particular, according to an 
estimate from the United Nations Population 
Division, 19% of all abortions in France registered 
since 2002 have occurred by taking RU-486. 
Moreover, in response to the COVID-19 
pandemic, France has extended access to 
medical abortion until the ninth week of 
pregnancy (17). 
In contrast, the Republic of Ireland has an 
extremely restrictive approach to abortion, 
SEEMEDJ 2021, VOL 5, NO. 1 Medical vs Surgical Abortion 
189 Southeastern European Medical Journal, 2021; 5(1) 
 
unless there are circumstances that put a 
woman’s health and life at risk. In Ireland, the 
constitution recognises the right to life for 
unborn children. Should such conditions arise 
that endanger the health of the woman and/or 
the child, however, the law does not set time 
limits for terminating pregnancy, though a 
surgical abortion is the only possible option (47). 
Regarding drugs used for medical abortion, 
there are only a few European countries where 
abortifacient drugs are not registered (45), or 
they are illegal or banned (46-51) (see Table 1). In 
the European Union, Malta is the only state that 
has banned both surgical and medical abortion 
(49). These differences between various 
European countries, from the north to the south 
of Europe, have historical, political and religious 
origins. Medical abortion in Spain, for example, is 
not easily accessible and it is very expensive. For 
these reasons, surgical abortions account for the 
majority of pregnancy termination procedures 
(44). Conversely, in Sweden, medical abortions 
accounted for 93% of all abortions in 2018 (19). 
Any woman who turns to a healthcare 
professional has the right to thorough and 
comprehensive consultations on abortion 
practices (also, and above all, in relation to the 
clinical condition of a pregnant woman) as well 
as on the risks and benefits of one method 
compared to the other. Consultation is advised, 
but not mandatory for adult women, while it is 
required for minors. The “contraceptive 
revolution”, or rather the introduction of the 
abortion pill, in fact, started in the 1960s and 
1970s in Western European countries, which 
were the first to legalise abortion and where, 
therefore, it is perceived as a fundamental right 
of all women. 
Italy: government legislation and abortion plan 
The high degree of sensitivity in Italy towards 
ethically and religiously contentious issues has 
most likely played a role in stymieing and 
delaying scientific progress in terms of access to 
abortion and medically assisted procreation 
(MAP) procedures.  
Based on Law 194 (“Norms on the Social 
Protection of Motherhood and the Voluntary 
Termination of Pregnancy”), women may legally 
resort to voluntary termination of pregnancy at 
national public facilities within the first 90 days 
of gestation, after which pregnancies may only 
be terminated for therapeutic purposes (5). 
Nevertheless, the share of conscientious 
objectors has grown by 12% over the past 10 
years, reaching as much as 90% in regions such 
as Molise, Trentino-Alto Adige and Basilicata. 
Significantly, in the whole region of Molise, there 
is currently only one registered physician who 
has not expressed a refusal to treat (11). 
In 2014, the European Committee of Social 
Rights of the Council of Europe formally 
reprimanded three hospitals in the central 
Marche region, Jesi, Fano and Fermo, where all 
medical personnel had expressed a refusal to 
treat. The Committee claimed that such a 
situation constituted a violation of women’s right 
to health, which is enshrined in the European 
Social Charter (52). 
Another element negatively affects medical 
abortion: in compliance with the 
recommendations issued by the High Council of 
Health, most Italian regions require women 
seeking abortifacient drugs, such as RU-486, to 
be hospitalised to terminate a pregnancy (53). 
Due to that requirement and the organisational 
and ethical challenges which it engenders, 
many facilities have mostly opted for surgical 
abortion instead, to the extent that in 2018, fewer 
than 25% of Italian women could resort to 
medical abortion (11). 
In December 2015, the Association of Italian 
Physicians for Contraception and Abortion 
(AMICA), counting on the support of various 
organisations and high-profile backers, sent an 
open letter to the Italian Ministry of Health, in 
which it asked to make medical abortion 
procedures less restrictive, on a day hospital 
basis and, where possible, accessible even in 
family counselling centres and ambulatory care 
facilities, for the sake of ensuring health care 
services availability and adequacy. On 8 August 
2020, the Ministry of Health updated the set of 
guidelines regulating access to the abortifacient 
drug RU-486, allowing for its administration on 
an outpatient basis, i.e. with no need for 
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hospitalisation, and even extending the ultimate 
time limit for abortion from the seventh to the 
ninth gestational week. Such a development, 
based on scientific evidence, undoubtedly 
constitutes a meaningful step forward for Italy in 
terms of fully enforcing Law 194/78. 
Nevertheless, such a consequential decision has 
occurred within an uneven socio-political 
context. As a matter of fact, the ministerial 
decision has been made on the heels of an 
opinion which was asked from the High Institute 
of Health, following a regulatory decision made 
by the regional government of Umbria. That 
opinion was meant to discourage the tendency 
on the part of regions to perform medical 
abortion on a day hospital basis. The Umbria 
legislative initiative followed the 2010 set of 
ministerial recommendations (53), after the 
Italian Medicines Agency (AIFA) had authorised 
the marketing and distribution of the drug in 
compliance with European standards, albeit with 
restrictions in place that do not apply in other 
countries, such as the three-day hospitalisation 
requirement and the seven-week gestational 
limit. 
The newly introduced ministerial directive has 
raised widespread controversy. The Legal 
Affairs Department of the regional government 
of Piedmont, in agreement with the Italian 
Episcopal Conference, has opposed the 
directive, arguing that it may run counter to Law 
194/78 and stressing that outpatient 
administration of RU-486 could lead to serious 
complications for women. 
Conclusion 
It is obviously essential that the new guidelines 
do not conflict with the original primary purpose 
of Law 194/78 in terms of providing sound 
healthcare and psychological consultations for 
women in order to “try to remove the underlying 
reasons that induce women to seek an abortion” 
(5). Furthermore, it is essential to guarantee 
access to follow-up support activities for those 
women who ultimately decide to terminate their 
pregnancies, for the purpose of ensuring the 
fetus is expelled in a complete and safe fashion 
in the interest of the patient’s well-being. 
Furthermore, the WHO itself has been 
advocating for medical abortion (4) over surgical 
abortion in light of the many advantages in terms 
of financial benefits for healthcare providers (as 
a result of fewer hospitalisations, reduced use of 
anaesthesia and fewer surgical procedures) and 
a higher degree of safety, given the lower rates 
of complications arising from surgical 
interventions, such as suction aspiration and 
curettage. Moreover, in cases where medical 
abortion is not carried out in a timely fashion, 
resorting to surgical abortion is inevitable, often 
as an emergency procedure, which increases 
the risk for patients to contract infections or 
haemorrhages during surgery (54, 55). 
The Italian ministerial directive is ultimately and 
consistently aimed at guaranteeing and 
upholding the “right to responsible and 
conscious procreation” by removing some of the 
barriers hindering access to termination of 
pregnancy and extending the period in which 
such procedures can be accessed, in an effort to 
discourage illegal abortions and reduce the 
need for late surgical abortions, often performed 
under emergency circumstances. 
The nationwide application of said ministerial 
decree, released on 8 August 2020, will make it 
possible to gather more consistent and reliable 
data as to the rates of adverse events associated 
with medical abortion, which will provide 
scientifically reliable analytical elements for 
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